VARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD

Similar documents
Introduction: Table/Figure Descriptions:

July VQAAB Minutes VQA Advisory Board (VQAAB) Members

VQA HIV DNA Control SOP Version 5.0 HIV DNA Testing 13 March 2012

VQA Control SOP Version 4.0 Roche Amplicor HIV-1 DNA Test, v August 2007

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26

Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/

Standardization: Calibration of. International Standards, reference preparations and working standards. Micha Nübling, PEI

Use of Viral Load Testing in Managing CMV Infections in SOTR

Panther has new prey

Središnja medicinska knjižnica

DKK-1 ELISA, Cat.No. BI For the quantitative determination of DKK-1 in human serum

Comparison of Quantitative and Qualitative PCR Assays for Cytomegalovirus DNA in Plasma

QIAsymphony DSP Circulating DNA Kit

AccuVert HIV-1 Seroconversion Panel PRB955 ( ) / Batch #

SAMENESS AND REDUNDANCY IN TARGET DETECTION AND TARGET COMPARISON. Boaz M. Ben-David and Daniel Algom Tel-Aviv University

1) Drop off in the Bi 150 box outside Baxter 331 or to the head TA (jcolas).

DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.

Mathematical Microbiologists: Why we have to return to our square roots to uncover uncertainty (of measurement) in Quantitative PCR (qpcr)

NIAID DAIDS FLOW CYTOMETRY LABORATORY CERTIFICATION

HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings

artus EBV QS-RGQ Kit Performance Characteristics May 2012 Sample & Assay Technologies Analytical sensitivity plasma

Laboratories That Offer the Ultra-senstive PCR Test to Individuals

BNP Fragment EIA (Cat.No. BI-20852W) For the Determination of BNP Fragment in Human Samples

Characterization and data assessment of NGS-based genotyping using VQA HIVDR proficiency panels

WHO recommendations. Diagnostic testing in infants

(DNA) Real-time PCR. Exicycler 96 Rotor-Gene Q/6000 PCR

The use of QCMD proficiency testing panels in clinical virology.

Experience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control

Development of a NIST Standard Reference Material for Cytomegalovirus

Technical Bulletin No. 161

Clinical trial design issues and options for the study of rare diseases

Week 17 and 21 Comparing two assays and Measurement of Uncertainty Explain tools used to compare the performance of two assays, including

Practical Aspects of Standardisation for a Global Controls Manufacturer

CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD

HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2017Apr19

CMV DNA Quantification Using an Automated Platform for Nucleic Acid Extraction and Real- time PCR Assay Set-up

External validation for CD4 and viral load assays: South African Experience

Results of the College of American Pathologists (CAP) Proficiency Program for CMV, EBV, and BKV Viral Load Testing

Final Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110

External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience

Hepatitis C Virus (RNA)A

A novel approach to estimation of the time to biomarker threshold: Applications to HIV

BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS

AccuSet HCV Performance Panel

Stability of native, lyophilized and inactivated standards

1) Drop off in the Bi 150 box outside Baxter 331 or to the head TA (jcolas).

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg

Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012

Non-competitive Internal Control Concept for PCR-based Qualitative Assays

Supplement to SCnorm: robust normalization of single-cell RNA-seq data

Hydroxyurea with ddi or ddi/d4t: a novel approach to HIV therapy

Clinical Study Report AI Final 28 Feb Volume: Page:

Interpreting quantitative HBV, HCV and HIV-1 nucleic acid testing

Standardization of Immune Biomarkers: Lessons From the HIV Field

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19

Quantification of HBV, HCV genotype and HIV subtype panels

Chronic HIV-1 Infection Frequently Fails to Protect against Superinfection

liquicolor Design Verification

liquicolor (AMP Buffer, IFCC) Design Verification

Application of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma

Case Studies, or Verification Vignettes

Anumber of clinical trials have demonstrated

Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age

HIV-1 AccuVert TM Seroconversion Panel

Proposal of a validation method for automated nucleic acid extraction and RT-qPCR analysis : an example with Bluetongue virus

altona DIAGNOSTICS altona DIAGNOSTICS RealStar CMV PCR Kit 1.0 always a drop ahead. 11/2012

HIV-1 AccuVert Seroconversion Panel (PRB966) / Batch #

Lecture Outline Biost 517 Applied Biostatistics I. Statistical Goals of Studies Role of Statistical Inference

Prior to site activation the following events were lined up

Simple Solutions for Patient Monitoring. Maximum Flexibility 2 Configuration: 8 to 1000 viral load tests/day 2 Sample: Plasma/DBS

WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: Abbott RealTime HIV-1 (m2000sp) Number: PQDx

Human Neurology 3-Plex A

AccuSet Anti-HIV-1 Mixed Titer Performance Panel

CMV Diagnostic Strategies: Current and Future

HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28

WHO Prequalification of Diagnostics Programme PUBLIC REPORT

Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials

Technical Bulletin No. 162

DOE Wizard Definitive Screening Designs

Design Verification IMTEC-TSH R -A C Intended Use... 2 Diagnostic Sensitivity and Diagnostic Specificity... 2 Interferences... 4 Imprecision...

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.

Molecular diagnosis of infectious disease - Method validation and environmental setting 傳染病的分子診斷 - 方法確認與環境背景. WC Yam 任永昌

Affordable tests for HIV drug resistance and HIV viral load in Africa Prof Tobias Rinke de Wit

Analysis of left-censored multiplex immunoassay data: A unified approach

Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials

B19 Virus EQA Programme Final Report QAV (B19DNA14)

WAGENINGEN EVALUATING PROGRAMS FOR ANALYTICAL LABORATORIES. Certificate of Analysis. International Plant-Analytical Exchange REFERENCE MATERIAL

LIPASE liquicolor. Design Verification. Multipurpose Reagent

Chapter 5 A Dose Dependent Screen for Modifiers of Kek5

S-01 SUPPORTING INFORMATION. TITLE: Inter-laboratory reproducibility of a targeted metabolomics platform for analysis of human serum and plasma

Natural History of HBV Infection

Evaluation of run controls for cobas 6800 MPX and HEV assay

The Human Cathelicidin LL37 Peptide has High Plasma Levels in B and C Hepatitis Related to Viral Activity but not to 25-Hydroxyvitamin D Plasma Level

5/20/ Administration & Analysis of Surveys

COMPARISON OF HIV DRUG-RESISTANT MUTANT DETECTION BY NGS WITH AND WITHOUT UNIQUE MOLECULAR IDENTIFIERS (UMI)

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.

Performance of an automated system for quantification of hepatitis C virus RNA

Statistical techniques to evaluate the agreement degree of medicine measurements

LAB ASSIGNMENT 4 INFERENCES FOR NUMERICAL DATA. Comparison of Cancer Survival*

Transcription:

VARIATION IN MEASUREMENT OF HIV RNA VIRAL LOAD SOURCES OF VARIATION (RANDOM VS SYSTEMATIC) MAGNITUDE OF EACH SOURCE CONSEQUENCES FOR CONFIDENCE LIMITS AROUND MEASUREMENTS AND CHANGES DATA FROM ROCHE HIV MONITOR ASSAY

SOURCES OF VARIATION 1) INTRA-ASSAY (AMONG REPLICATES IN A BATCH) 2) INTER-ASSAY (AMONG REPLICATES IN DIFFERENT BATCHES) 3) INTRA-KIT (AMONG KIT LOTS) 4) INTER-KIT (E.G. ROCHE VS OT NASBA) 5) INTER-LAB (SAME KIT) 6) BIOLOGICAL FLUCTUATION (EVEN IF NO SYSTEMATIC CHANGE) ASSUME A PATIENT IS FOLLOWED OVER TIME WITHIN A LAB FOCUS ON 1), 2), 6), THEN ON 3)

MODELING APPROACH FOR ASSAY, BIOLOGICAL VARIATION AND TOTAL ASSUME THAT DATA ARE NORMALLY DISTRIBUTED AND VARIANCES ARE ADDITIVE: V TOT = V B + V E + V A WHERE V TOT = OVERALL VARIANCE V B = BIOLOGICAL VARIANCE V E = INTER-ASSAY VARIANCE V A = INTRA-ASSAY VARIANCE S TOT = V B + VE + VA IN BATCHED ASSAYS: S TOT = V B + VA

APPROACH TO ESTIMATION ESTIMATE TOTAL VARIANCE (BIOLOGICAL PLUS ASSAY) ESTIMATE ASSAY VARIANCE OBTAIN BIOLOGICAL VARIANCE BY SUBTRACTION OBTAIN STANDARD DEVIATIONS FROM VARIANCES

SD TOT FOR BATCH TESTING 10 TH -90 TH LINEAR PERCENTILES STUDY N MODELS OF DIFFERENCES ACTG 076 55 0.27 0.28 ACTG 175, A 95 0.13 0.14 ACTG 175, B 87 0.27 0.16 ACTG 175, C 110 0.27 0.16 ACTG 229 259 0.29 0.21 WITS 57 0.23 0.25 COMBINED 663 0.26 0.18 10%-90% OF DIFFERENCE: 1.8 SD TOT ASSAY SD S FROM THE VQA STANDARDS STANDARD DEVIATION RUNS INTRA-ASSAY INTER-ASSAY ACTG 076 48 0.15 0.08 ACTG 175, A 26 0.09 0.05 ACTG 175, B 20 0.09 0.08 ACTG 175, C 37 0.09 0.10 COMBINED 131 0.12 0.08

ASSAY SD S FROM PROFICIENCY PANELS INTRA-ASSAY SD, ALL PARTICIPATING LABORATORIES PANEL LABS SOURCE MEDIAN RANGE 06R 22 SPIKED SAMPLES 0.15 0.06-0.22 22 HIV+ PATIENTS 0.16 0.07-0.48 07R 22 SPIKED SAMPLES 0.12 0.07-0.35 22 HIV+ PATIENTS 0.12 0.07-0.50 INTRA-ASSAY SD, LABORATORIES WITH ACCEPTABLE PERFORMANCE PANEL LABS SOURCE MEDIAN RANGE 06R 20 SPIKED SAMPLES 0.11 0.06-0.20 17 HIV+ PATIENTS 0.12 0.07-0.20 07R 19 SPIKED SAMPLES 0.09 0.07-0.17 18 HIV+ PATIENTS 0.09 0.07-0.21 INTER-ASSAY SD SOURCE ALL LABS LABS W/C S VQA CONTROLS 0.15 0.14 HIV-INFECTED PATIENTS 0.08 0.08

BIOLOGICAL VARIATION REAL TIME TESTING: BATCH TESTING: V TOT = V B + V E + V A V TOT = V B + V A BIOLOGICAL SD: S B = (V TOT - V A ) 1/2 % OVERALL VARIATION: 100*V B /V TOT BIOLOGICAL VARIATION S TOT S A S B 100*V B /V TOT 0.26 0.12 0.23 80 0.18 0.12 0.13 56

SD INTRA-ASSAY SD VS NOMINAL CONCENTRATION, RT-PCR ASSAYS ON PP06R, PP07R 6 ˆ A C AA AC 5 ˆ BD BE AA **DC A CF** A AE CC A BA AB **GF 4 ˆ A CB** B D BD A G BE **K** AE A AA E A BA J AB F 3 ˆ DD F **GB CF** CD E B AA 2 ˆ A A 1 ˆƒˆƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒ 3 4 5 6 LOG 10 (NOMINAL CONCENTRATION) RNA COPIES/ML

SD INTRA-ASSAY SD OF LOG 10 (RNA) VS NOMINAL CONCENTRATION - ON PP06R, PP07R 0.5 ˆ A A A 0.4 ˆ A A A A 0.3 ˆ A A B AA A A A A A C A A A 0.2 ˆ C C B C AA B B A AC F B B AA G AB B A **D** AA B **BB D BA BC 0.1 ˆ AE** C **EC BC** DC D B ** **CC CC E CA CB BA A AG BE C H BE AA A AA AB A A AA 0.0 ˆƒƒˆƒƒƒƒƒƒAƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒ 3 4 5 6 LOG 10 (NOMINAL CONCENTRATION) RNA COPIES/ML

95% CONFIDENCE LIMITS (CL) FOR ESTIMATED RNA COPY NUMBER ASSUMING THE BIOLOGICAL SD=0.23. STANDARD DEVIATION 95% CL S A S E S TOT LOG 10 RNA @ 10 4 COPIES/ML 0.12-0.26 +0.51 3,100-32,000 0.20 0.30 +0.60 2,500-40,000 0.25-0.34 +0.67 2,100-47,000 0.12 0.08 0.27 +0.53 3,000-34,000 0.12 0.15 0.30 +0.59 2,500-39,000 0.20 0.08 0.32 +0.62 2,400-42,000 0.20 0.15 0.34 +0.67 2,100-47,000 0.25 0.08 0.35 +0.68 2,100-48,000 0.25 0.15 0.37 +0.73 1,900-54,000 S A : INTRA-ASSAY SD S E : INTER-ASSAY SD S TOT : TOTAL SD

STANDARD DEVIATIONS FOR TWO VQA STANDARDS IN FIVE LABORATORIES SD LAB RUNS 1,500 COPIES/ML 15,000 COPIES/ML A 191 0.27 0.25 B 102 0.20 0.21 C 65 0.23 0.18 D 75 0.19 0.16 E 58 0.28 0.21

MEDIAN LOG10 RECOVERY FOR EACH QS LOT IN EACH LABORATORY. DASHES: <8 TOTAL ASSAYS PER QS LOT IN THAT LABORATORY. P: P- VALUE FOR DIFFERENCES AMONG QS LOTS WITHIN EACH LABORATORY. QS INPUT COPIES LAB 72 78 79 81 82 87 1 87 2 88 91 P A 0.32-0.03-0.18 0.09 0.24 0.11 <0.001 B -0.12-0.11-0.15-0.06 0.21 0.05 <0.001 C -0.06-0.10 0.09 0.004 0.0047 D 0.12 0.013 0.12 <0.001 E 0.19 0.10 0.17 0.081 ALL -0.09 0.18-0.06-0.17-0.07 0.12 0.04 0.19 0.06

EFFECTS OF QS VARIATION ON A HYPOTHETICAL STUDY ASSUMPTIONS LONGITUDINAL STUDY WITH ASSAYS IN REAL TIME 2 QS LOTS USED IN SUCCESSION LOT CHANGE OCCURS BETWEEN TWO PATIENT VISITS 95% CL FOR THE DIFFERENCE IN RNA BETWEEN VISITS 0.20 ± 1.96S TOT 2 = 0.20 ± 0. 72, IF S TOT = 0. 26 IF NEW LOT READS 0.20 LOG10 HIGHER THAN OLD, P(APPARENT 3-FOLD INCREASE) = 0.33 P(APPARENT INCREASE IS CONFIRMED) = 0.10 IF NEW LOT READS 0.30 LOG10 HIGHER THAN OLD, P(APPARENT 5-FOLD INCREASE) = 0.14 P(APPARENT INCREASE IS CONFIRMED) = 0.02

MEDIAN LOG10 RECOVERY FOR EACH QS LOT IN EACH LABORATORY FOR THE 150-COPY STANDARD ON THE ULTRANSENSITIVE MONITOR ASSAY. QS INPUT COPIES LAB 72 74 76 78 82 82.5 87 88 91 P A -0.03-0.22 0.038 B -0.39 0.05 0.003-0.02-0.42-0.02-0.03 0.08 0.03 <0.001 C 0.16-0.08 0.07 0.03 0.004 0.004 0.24 D -0.29-0.28 0.80 E -0.32 0.28-0.14 0.17 <0.001 QS LOTS IN CHRONOLOGICAL ORDER QS INPUT COPIES LAB 72 82 78 88 87 76 82.5 91 74 P A -0.03-0.22 0.038 B -0.39-0.42-0.02 0.08-0.03 0.003-0.02 0.03 0.05 <0.001 C 0.07 0.004-0.08 0.03 0.004 0.16 0.24 D -0.29-0.28 0.80 E -0.32-0.14 0.28 0.17 <0.001

SUMMARY TOTAL STANDARD DEVIATION: 0.18 0.26 INTRA-ASSAY SD: 0.12 IN PROFICIENT LABORATORIES INTRA- + INTER-ASSAY SD: 0.14-0.17 BIOLOGICAL SD: 0.13-0.23 BIOLOGICAL VARIANCE (BATCH): 56-80% OF TOTAL ASSAY VARIANCE (BATCH): 20-44% OF TOTAL LOT-TO-LOT VARIATION: SYSTEMATIC COMPONENT USUALLY SMALL SHOULD BE VERIFIED FOR NEW LOTS